Medium-to-long term outcomes of bioresorbable scaffold treatment in patients with acute coronary syndrome

Table 3 Clinical follow-up outcome, n (%)

Clinical outcome	6 months			1 year			2 years			3 years
	Observation group	Control group	P value	Observation group	Control group	P value	Observation group	Control group	P value	Observation group	Control group	P value
Follow-up patients	52 (95)	69 (95)	0.65	48 (87)	63 (86)	0.73	43 (78)	60 (82)	0.14	32 (37)	46 (40)	0.34
Main end point
DoCE	2 (4)	3 (4)	0.19	7 (15)	6 (10)	0.03a	9 (31)	11 (13)	0.08	5 (16)	7 (15)	0.22
CD	0 (0)	0 (0)	-	0 (0)	0 (0)	-	1 (2)	1 (2)	0.52	1 (3)	2 (4)	0.18
ScT	1 (2)	2 (3)	0.84	2 (4)	2 (3)	0.53	2 (7)	3 (5)	0.14	3 (9)	5 (11)	0.34
TV-MI	1 (2)	1 (1)	0.75	2 (4)	2 (3)	0.07	2 (5)	3 (5)	0.12	2 (6)	4 (8)	0.07
TLR	0 (0)	0 (0)	-	3 (6)	3 (5)	0.35	4 (9)	4 (7)	0.06	3 (9)	5 (11)	0.53
Secondary end point
TVR	0 (0)	0 (0)	-	0 (0)	0 (0)	-	1 (2)	2 (5)	0.01a	2 (6)	2 (4)	0.33
CBG	0 (0)	0 (0)	-	0 (0)	0 (0)	-	0 (0)	0 (0)	-	1 (3)	0 (0)	0.85
Non-cardiogenic death	0 (0)	2 (3)	0.65	0 (0)	1 (2)	0.11	2(5)	1 (2)	0.73	1 (3)	2 (4)	0.49

^aP < 0.05.

CD: Cardiac death; CBG: Coronary bypass grafting; DoCE: Device-oriented composite endpoint; ScT: Scaffold thrombosis; TV-MI: Target-vessel myocardial infarction; TLR: Target-lesion revascularization; TVR: Target-vessel revascularization.